{
  "source": "PA-Notification-Doxepin-cream-Prudoxin-Zonalon.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1205-9\nProgram Prior Authorization/Notification – doxepin cream\nMedication Prudoxin®* (doxepin), Zonalon®* (doxepin)\nP&T Approval Date 12/2016, 12/2017, 12/2018, 1/2020, 3/2021, 3/2022, 3/2023, 3/2024,\n4/2025\nEffective Date 7/1/2025\n1. Background:\nPrudoxin and Zonalon cream are indicated for the short-term (up to 8 days) management of\nmoderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Prudoxin* or Zonalon* will be approved based on the following criteria:\na. Diagnosis of moderate pruritus due to one of the following:\n(1) Atopic dermatitis\n-OR-\n(2) Lichen simplex chronicus\nInitial authorization will be issued for 1 month\nB. Reauthorization\n1. Prudoxin* or Zonalon* will be approved based on both of the following criteria:\na. Diagnosis of moderate pruritis due to either atopic dermatitis or lichen simplex\nchronicus\n-AND-\nb. Documentation of positive clinical response to therapy\nReauthorization will be issued for 1 month\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Brand Prudoxin and Zonalon are typically excluded from coverage.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Prudoxin [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.\n2. Zonalon [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.\nProgram Prior Authorization/Notification – doxepin crea",
    "t]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.\n2. Zonalon [package insert]. Ltd. San Antonio, TX: DPT Laboratories, Ltd; June 2017.\nProgram Prior Authorization/Notification – doxepin cream\nChange Control\nDate Change\n12/2016 New program.\n12/2017 Annual review with no changes.\n12/2018 Annual review. Updated references.\n1/2020 Annual review. Updated references.\n3/2021 Updated to note brand Zonalon is typically excluded from coverage.\n3/2022 Updated to note brand Prudoxin is typically excluded from coverage.\nAdded indication requirement to reauthorization section.\n3/2023 Annual review. Added state mandate language.\n3/2024 Annual review. No changes.\n4/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}